MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, analysis-driven pharmaceutical-excellent cannabis extraction, distillation and derivative solutions, currently announced it will provide cannabis concentrate solutions in Denmark to two new healthcare cannabis clients below two separate white-label agreements. These clients will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed solutions to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal solutions two years ago as aspect of a 4-year pilot system. The system supplies individuals with secure item access and national wellness authorities with patient information that they can use to recognize usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mainly ladies amongst the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians below this system in 2019.
“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent a different step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare market place with new and revolutionary healthcare cannabis focused solutions positions us for further development in Europe and adds to MediPharm Labs all-essential physique of understanding that we are leveraging to improve the design and style of our formulations for individuals and shoppers everywhere.”
Beneath the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its clients to commence in October 2020, pending regulatory approval by applicable wellness authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured numerous extremely eye-catching domestic and international provide agreements with higher excellent partners, now such as new clients in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new company wins are a clear and essential validation of our choice to construct a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production below all of these agreements.”
MediPharm Labs Australia received its Superior Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, such as Denmark. The Firm entered into its very first European white-label cannabis provide agreement that exact same month with Therismos Restricted.
About Denmark’s Health-related Cannabis Market place
Denmark launched its 4-year healthcare cannabis pilot system on January 1st, 20181. Post-harvest Superior Manufacturing Processes (GMP) is needed for distribution of healthcare cannabis solutions in Denmarktwo.
Via the system, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 places: discomfort brought on by numerous sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy remedy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive evaluation of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical excellent cannabis oil and concentrates and sophisticated derivative solutions using a Superior Manufacturing Practices certified facility with ISO typical constructed clean rooms. MediPharm Labs has invested in an specialist, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 key extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its clients. Via its wholesale and white label platforms, they formulate, customer-test, method, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
For additional details, please speak to:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E-mail: [email protected]
Internet site: www.medipharmlabs.com
1 Medicinal Cannabis Pilot Plan. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Health-related Cannabis Market place in Denmark & Europe. Retrieved: https://www.openaccessgovernment.org/the-healthcare-cannabis-market place-in-denmark-europe/80721/
three The Danish Health-related Cannabis Pilot Programme: Placing the Patient Initial. Retrieved: https://www.healtheuropa.eu/the-danish-healthcare-cannabis-pilot-programme-placing-the-patient-very first/92991/
CAUTIONARY NOTE Concerning FORWARD-Searching Info:
This news release consists of “forward-searching information” and “forward-searching statements” (collectively, “forward-searching statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-searching statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that includes discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (typically but not constantly employing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or benefits “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and may perhaps be forward-searching statements. In this news release, forward-searching statements relate to, amongst other points, the thriving overall performance of the agreements and shipping of solutions thereunder as planned further development in Europe and enhancing the design and style of formulations. Forward-searching statements are necessarily primarily based upon a quantity of estimates and assumptions that, when thought of affordable, are topic to identified and unknown dangers, uncertainties, and other aspects which may perhaps lead to the actual benefits and future events to differ materially from these expressed or implied by such forward-searching statements. Such aspects incorporate, but are not restricted to: common company, financial, competitive, political and social uncertainties the inability of MediPharm Labs to get sufficient financing the delay or failure to acquire regulatory approvals and other aspects discussed in MediPharm Labs’ filings, obtainable on the SEDAR site at www.sedar.com. There can be no assurance that such statements will prove to be correct, as actual benefits and future events could differ materially from these anticipated in such statements. Accordingly, readers need to not spot undue reliance on the forward-searching statements and details contained in this news release. Except as needed by law, MediPharm Labs assumes no obligation to update the forward-searching statements of beliefs, opinions, projections, or other aspects, need to they alter.